Know Cancer

or
forgot password

Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major


N/A
18 Years
N/A
Not Enrolling
Both
Thalassemia Major

Thank you

Trial Information

Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major


- In the first phase of the study we will develop a panel of reagents designed to
identify predominant thalassemia mutations in the Iranian population, as well as
alternative highly variable erythroid specific polymorphisms. To determine how
informative this panel is, these reagents will be applied to samples collected from
patients homozygous for the disorder, and compared to patients with thalassemia trait
and normal Iranian donors.

- In the second phase, we propose to serially measure and compare erythroid lineage
chimerism with overall genomic chimerism following transplant. Samples will be
collected from participants before and at 1, 2, 3, 6 and 12 months following transplant
and cryopreserved. Peripheral blood from the stem cell donor will also be collected
and cryopreserved. Participants will undergo myeloablative or nonmyeloablative
transplant.


Inclusion Criteria:



- Thalassemia patients being treated at Shariati Hospital in Tehran.

Type of Study:

Observational

Study Design:

Time Perspective: Retrospective

Principal Investigator

Catherine Wu, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute

Authority:

United States: Institutional Review Board

Study ID:

04-078

NCT ID:

NCT00480506

Start Date:

April 2004

Completion Date:

October 2005

Related Keywords:

  • Thalassemia Major
  • chimerism
  • allogenic hematopoietic transplantation
  • assay
  • Beta-Thalassemia
  • Thalassemia

Name

Location

Dana-Farber Cancer InstituteBoston, Massachusetts  02115